Stock Price Movements, Official Platinum Sponsor Status, Conference Schedules, Appointments and Clinical Trial Results - Analyst Notes on Intuitive, Agilent, Teleflex, WuXi PharmaTech, and Pacira
NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), Agilent Technologies Inc. (NYSE: A), Teleflex Incorporated (NYSE: TFX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Intuitive Surgical, Inc. Analyst Notes
On March 3, 2014, Intuitive Surgical, Inc.'s (Intuitive Surgical) stock went up by 2.03% to $453.84. In the past three trading days, Intuitive Surgical's shares declined 3.53%, compared to the Nasdaq Composite Index which went down by 0.34% during the same trading period. The full analyst notes on Intuitive Surgical, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ISRG/report.pdf
--
Agilent Technologies Inc. Analyst Notes
On March 3, 2014, Agilent Technologies Inc. (Agilent Technologies) reported that its tissue-based cancer diagnostics business, Dako, is the official Platinum Sponsor of 2014 annual meeting of the United States and Canadian Academy of Pathology (USCAP) at the San Diego Convention Center in San Diego, California. According to the Company, Dako will showcase its entire portfolio of integrated pathology solutions, designed with pathologists and laboratory staff in mind, at the exhibition booth No. 552. Commenting on the update, Britt Meelby Jensen, Dako's General Manager and Agilent Technologies' Vice President, stated, "Dako is proud to once again be the official Platinum Sponsor of the USCA. This is one of the best-organized and most-attended pathology congresses, and we see it as a key opportunity to reach the pathology community. We look forward to meeting with the many attendees who share our commitment to the fight against cancer." The full analyst notes on Agilent Technologies Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/A/report.pdf
--
Teleflex Incorporated Analyst Notes
On February 25, 2014, Teleflex Incorporated (Teleflex) reported that its Chairman, President and CEO, Benson F. Smith, is scheduled to speak at the Barclays Global Healthcare Conference on March 11, 2014, at the Loews Hotel, starting at 3:15 p.m. ET. Additionally, Teleflex stated that an audio webcast and accompanying slide presentation of the event will be made available on the Company's website under the investor section. The full analyst notes on Teleflex Incorporated are available to download free of charge at:
http://www.AnalystsReview.com/03052014/TFX/report.pdf
--
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On February 26, 2014, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that Dr. Hua Mu has joined the Company as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit. According to the Company, in the new role Dr. Hua Mu will report to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. Commenting on the appointment, Dr. Li stated, "I am delighted to welcome Hua to WuXi's leadership team. Hua brings extensive experience, particularly in clinical development in China, that is very critical for WuXi to help our partners bring their innovations to China and to develop innovative drugs to benefit Chinese patients." The full analyst notes on WuXi PharmaTech (Cayman) Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/WX/report.pdf
--
Pacira Pharmaceuticals Inc. Analyst Notes
On February 27, 2014, Pacira Pharmaceuticals Inc. (Pacira) announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. According to Pacira, the Phase 3 trial evaluated 183 patients who were randomized to receive either 266 mg of EXPAREL or placebo, with all patients offered rescue narcotics as needed. Commenting on the results of the trial, Dave Stack, President, CEO and Chairman of Pacira, stated, "We are pleased to report the positive results of the femoral nerve block trial and look forward to filing for a nerve block indication. We believe that the expansion of the EXPAREL label to include nerve block will further enhance its clinical utility and broaden its access among anesthesiologists and surgeons." The full analyst notes on Pacira Pharmaceuticals Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/PCRX/report.pdf
----
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article